sorafenib has been researched along with Hypoglycemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beil, W; Holstein, A; Kovacs, P | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Bihan, H; Cohen, R; Coindre, JM; Des Guetz, G; Le Jeune, S; Mourad, JJ | 1 |
3 other study(ies) available for sorafenib and Hypoglycemia
| Article | Year |
|---|---|
Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Interactions; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib | 2013 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Solitary Fibrous Tumors; Sorafenib | 2013 |